For HER2-enriched BC, the identification of Everolimus-FLCN reinforces the therapeutic potential of mTOR pathway inhibition, aligning with previous studies that have demonstrated Everolimus’s effectiveness in HER2-positive BC [60]. Here, ERBB2 is linked to breast cancer.